Nanobiotix at ASCO 2020

Founded in 1964, the American Society of Clinical Oncology (ASCO) is the world's leading professional organization for physicians and oncology professionals caring for people with cancer. With more than 35,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals.

Due to the actual COVID-19 crisis and for health and safety reasons, the 2020 annual meeting will be held Virtual from May 29 - 31.

This year’s ASCO 2020 theme is Unite and Conquer: Accelerating Progress Together. The Virtual Scientific Program will offer unique opportunities for participants from around the world to engage in education regarding state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field. The Meeting offers healthcare professionals providing oncology care an important opportunity to come together to explore the latest advances in science; contextualize recent discoveries and optimize treatment and research strategies; frame and critically evaluate major controversies in the field; and network with peers in an environment charged with the excitement of a common goal: progress toward better outcomes for patients.

Join us at ASCO20 Virtual!

We will be presenting new valuable data evaluating the potential of NBTXR3 to improve treatment outcomes for elderly patients. We will be sharing an update of our ongoing studies in Head & Neck and Immuno-Oncology (trial in progress). Nanobiotix is committed to changing the face of cancer therapy by bringing nanophysics to the heart of the cell.

We are proud to have two abstracts approved for the digital poster presentation. The posters will be released on the ASCO20 Virtual website at 8.00am ET on Friday, May 29. You can find more information about this by visiting the ASCO website or view our abstracts through the links below:


Abstract/Poster: 6573 ● 234 View the abstract here.

Abstract Title: Phase I trial of hafnium oxide nanoparticles activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients.
Session Title: Head and Neck Cancer
Presenter: Pr. Christophe Le Tourneau


Abstract/Poster: TPS3173 ● 237 View the abstract here.

Abstract Title: Phase I study of NBTXR3 activated by radiotherapy in patients with advanced cancers treated with an anti-PD-1 therapy.
Session Title: Developmental Therapeutics—Immunotherapy
Presenter: Dr. Colette Shen

Register on ASCO Annual Meeting Website